"Mologic said it will invest a part of an expansion to its $4.9m grant from the Bill and Melinda-Gates Foundation to finance access to Sherlock's INSPECTR™ platform, which the Cambridge-based US company licences earlier this year from the Wyss Institute.
Under the agreement, Mologic will provide its lateral flow-based platform CARD, which has been demonstrated to provide a 1,000-fold improvement in sensitivity over current technology, and its immunoassay platform ELTABA for enzyme activity detection. Sherlock Bioscience will provide its synthetic biology-based INSPECTR™ platform, which consists of a DNA hybridization-based sensor that can be easily programmed to detect target nucleic acids (DNA or RNA) with single base pair specificity, coupled with a paper-based synthetic gene network that translates the sensor’s detection into a bioluminescent signal that is easily visualised or captured on instant film. Crucially, this process can be done at room temperature and does not require any instrumentation."
https://european-biotechnology.com/up-to-date/latest-news/ne...